GET DAILY SIGNALSWhy Is iRadimed Corporation (IRMD) Stock Down -7.86% Today?
Key Takeaways
- IRMD shares fell 7.86% to approximately $79.00, down from a prior close of $85.74.
- The decline followed third-quarter 2026 results that met earnings expectations but failed to clear an elevated bar set by a premium valuation.
- Revenue beat consensus, yet investors focused on the pace of the MRidium 3870 pump ramp and the outlook for margin recovery.
- The stock has underperformed the broader market in 2026, reflecting skepticism that has built since a mixed second-quarter report.
- Traders are watching fourth-quarter execution, gross-margin trends, and whether management can reach its $100 million revenue run-rate target.
- For deeper context, explore Price Targets, Earnings, and Forecast pages for IRMD.
- Discover which strategies are leading under current conditions by exploring Trending AI Robots.
Opening Summary
IRMD, the stock of iRadimed Corporation, a Florida-based maker of MRI-compatible medical devices including its MRidium non-magnetic intravenous infusion pumps and patient-monitoring systems, fell 7.86% on Friday. Shares traded near $79.00, down from a prior session close of $85.74. The move lower came even as the company reported third-quarter earnings per share of $0.55, in line with analyst estimates, and revenue of $24.2 million, above the consensus of roughly $23.47 million. The market reaction signals that in-line results were not enough to satisfy investors who had already priced in a second-half growth acceleration.
Earnings Results: A "Sell the News" Reaction
The immediate catalyst for the decline was the company's third-quarter report. While IRMD matched the Street's earnings estimate and modestly exceeded the revenue forecast, the results landed against a backdrop of heightened expectations. Ahead of the report, the stock carried a premium multiple of roughly 44 to 49 times trailing earnings, a valuation that effectively assumed a decisive reacceleration tied to the launch of its next-generation 3870 MRI infusion pump.
Because the headline numbers largely matched the consensus rather than exceeding it, the report gave investors little new reason to defend that premium. The pattern reflects a classic earnings-driven "sell the news" move, where solid results are treated as disappointing simply because so much optimism was already reflected in the share price.
Pump Ramp and Margin Concerns
A secondary driver behind the pressure is ongoing uncertainty about the 3870 pump production ramp. Management had signaled a steep step-up in shipments during the third quarter, alongside the beginning of a gross-margin recovery following manufacturing inefficiencies that pushed gross margin down to 74% in the second quarter from 78% a year earlier. The market has been watching closely for evidence that rising volumes would spread fixed costs and restore margins toward historical levels.
With shares already having declined through the second half of the year and a Needham analyst initiating coverage with a Hold rating in September on the view that optimism was "largely priced in," investors entered this report wanting proof of execution rather than promises. The subdued reaction suggests that questions about how quickly the factory can absorb demand remain unresolved.
Market Context and Trading Activity
The decline in IRMD unfolded on elevated trading activity relative to the relatively light sessions seen in the days leading into the report, consistent with investors repositioning around earnings. Technically, the stock has been trading below its 200-day moving average, and Friday's move pushed it deeper into the lower half of its recent range and further below its 52-week high.
The move also diverged from the broader market tone. The Nasdaq Composite has advanced solidly in 2026, while IRMD has underperformed significantly on a year-to-date basis. That divergence underscores the stock-specific nature of the selling pressure rather than a broad sector or macro-driven pullback.
What Comes Next for IRMD
Looking ahead, investors will focus on whether IRMD can translate its order book and pricing power into sustained revenue growth and margin repair in the fourth quarter. Key areas of attention include 3870 shipment volumes, the mix of higher-priced quad-channel systems, disposables and monitoring momentum, and management's commentary on reaching a $100 million annualized revenue run rate.
Risks remain concentrated. The growth story hinges on a narrow portfolio led by a single MRI-safe pump line, and any production, supply-chain, or demand stumble could show up quickly for a company of this size. The premium valuation also leaves limited room for error, meaning execution across the next two quarters will be critical to restoring investor confidence.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, but only the strongest performers under current market conditions are highlighted in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving investors a way to monitor automated approaches that are adapting to shifting conditions. Explore the Trending AI Robots page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IRMD's RSI Oscillator leaves overbought zone
The 10-day RSI Oscillator for IRMD moved out of overbought territory on October 15, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 instances where the indicator moved out of the overbought zone. In 23 of the 32 cases the stock moved lower in the days that followed. This puts the odds of a move down at 72%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRMD as a result. In 80 of 114 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
The Moving Average Convergence Divergence Histogram (MACD) for IRMD turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 35 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 66%.
IRMD moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for IRMD crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.
Following a +0.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRMD advanced for three days, in 192 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
IRMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 215 of 266 cases where IRMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 16 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. IRMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.775) is normal, around the industry mean (3.870). P/E Ratio (47.370) is within average values for comparable stocks, (1.382). Projected Growth (PEG Ratio) (1.180) is also within normal values, averaging (11.052). Dividend Yield (0.009) settles around the average of (0.010) among similar stocks. P/S Ratio (12.315) is also within normal values, averaging (40.124).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of non-magnetic intravenous infusion pump systems
Industry MedicalNursingServices
Advertisement